Loading clinical trials...
Loading clinical trials...
A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19
Conditions
Interventions
convalescent plasma from recovered COVID 19 donor
Locations
14
Saudi Arabia
John Hopkins Aramco Healthcare
Dhahran, Eastern Provence, Saudi Arabia
Qatif Central Hospital
Al Qaţīf, Saudi Arabia
Dammam Medical Complex
Dammam, Saudi Arabia
Imam Abdulrahman Bin Faisal University
Dammam, Saudi Arabia
king Fahad specialist hospital
Dammam, Saudi Arabia
DHahran Military Medical Complex
Dhahran, Saudi Arabia
Start Date
April 18, 2020
Primary Completion Date
November 1, 2020
Completion Date
November 16, 2020
Last Updated
November 16, 2021
Lead Sponsor
King Fahad Specialist Hospital Dammam
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions